60 Degrees Pharmaceuticals, Inc. 今日对外公布，其针对住院巴贝斯虫病患者的临床研究已成功达成最低入组人数这一关键里程碑。这一进展标志着该项目的推进迈出了坚实一步。
公司同时明确，计划在2026年10月6日之前，对外发布该研究的中期数据解读。这一时间表的设定，为市场及医学界提供了清晰的预期。巴贝斯虫病作为一种罕见且可能危及生命的寄生虫感染，目前有效的治疗选择十分有限，因此这项研究的每一步进展都备受关注。
围绕此项研究的后续动态，尤其是即将公布的中期数据，投资者和行业观察者都将予以密切关注。这些数据或将为评估相关治疗方案的潜力提供重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.